Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etavopivat

- PMLiVE

Novo opens doors on new US headquarters

$225m redevelopment for New Jersey life science offices

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

- PMLiVE

Novo Nordisk posts ‘robust’ gains in sales and earnings

Diabetes drug Victoza and insulin analogue portfolio see strong growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links